Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Graefe's Archive for Clinical and Experimental Ophthalmology
Literature
1.
Yannuzzi LA, Bardal AM, Freund KB, Chen KJ, Eandi CM, Blodi B (2006) Idiopathic macular telangiectasia. Arch Ophthalmol 124:450–460PubMedCrossRef
2.
Engelbrecht NE, Aaberg TM Jr, Sung J, Lewis ML (2002) Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis. Arch Ophthalmol 120:320–324PubMed
3.
Kovach JL, Rosenfeld PJ (2009) Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II. Retina 29:27–32PubMedCrossRef
4.
Snyers B, Verougstraete C, Postelmans L, Leys A, Hykin P (2004) Photodynamic therapy of subfoveal neovascular membrane in type 2a idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol 137:812–819PubMedCrossRef
5.
Berger AS, McCuen BW 2nd, Brown GC, Brownlow RL Jr (1997) Surgical removal of subfoveal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Retina 17:94–98PubMedCrossRef
6.
Jorge R, Costa RA, Calucci D, Scott IU (2007) Intravitreal bevacizumab (avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol 245:1045–1048PubMedCrossRef
7.
Mandal S, Venkatesh P, Abbas Z, Vohra R, Garg S (2007) Intravitreal bevacizumab (avastin) for subretinal neovascularization secondary to type 2a idiopathic juxtafoveal telangiectasia. Graefes Arch Clin Exp Ophthalmol 245:1825–1829PubMedCrossRef
8.
Rishi P, Shroff D, Rishi E (2008) Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (srnvm) associated with type 2 idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 246:619–621PubMedCrossRef
Metadata
Title
Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia
Authors
Lazaros Konstantinidis
Irmela Mantel
Leonidas Zografos
Aude Ambresin
Publication date
01-11-2009
Publisher
Springer-Verlag
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 11/2009
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-009-1117-3

Other articles of this Issue 11/2009

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2009 Go to the issue

Retinal Disorders

Heavy silicone oil (Densiron-68) for the treatment of persistent macular holes

Letter to the Editor

Is intravitreal bevacizumab treatment effective in diffuse diabetic macular edema?

Letter to the Editor

Image analyses of conjunctival hyperemia in guinea pig allergic conjunctivitis

Medical Ophthalmology

Histochemical and immunohistochemical profile of human and rat ocular medial rectus muscles

Basic Science

Mechanical force enhances MMP-2 activation via p38 signaling pathway in human retinal pigment epithelial cells

Retinal Disorders

Equivalent tamponade by room air as compared with SF6 after macular hole surgery